TNF and rheumatoid arthritis: Up to now, bDMARDs approved for RA therapy include agents with five different modes of action: TNF inhibition, T-cell co-stimulation blockade, IL-6 receptor inhibition, B-cell depletion, and interleukin-1 inhibition.